MGTI Multi Billion dollar company in the making!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the most undervalued stock on the OTCQB. This company is worth $25-$50 Million conservatively. The team in place and the 11 vaccines and counting all life threatening un met medical needs. We will see a quadruple from here at the very least.
GOVX Pipeline
https://www.geovax.com/clinical-pipeline.html
NVAX Pipeline
http://novavax.com/page/11/clinical-stage-pipeline
Here is the distinction GOVX has three of the worlds top vaccine scientists.. NVAX doesn't
#2 Rated Vaccine Scientist in the world Dr Thomas Monath
https://www.bloomberg.com/research/stocks/private/person.asp?personId=438538&privcapId=9206677
#5 Rated Vaccine Scientist in the world Dr Stan Plotkin
Emeritus ProfessorUniversity of Pennsylvania ProfessorJohns Hopkins University.
https://en.wikipedia.org/wiki/Stanley_Plotkin
#22 Rated Vaccine Scientist in the world Dr Farshad Guirakhoo Chief Scientific Officer for GOVX.
Dr. Guirakhoo joined GeoVax as Senior Vice President of Research and Development in October 2015 and was promoted to Chief Scientific Officer in January 2017. Dr. Guirakhoo was named one of the ‘50 Most Influential People in Vaccines’ in Vaccine Nation’s 2014 list. His previous assignment was Chief Technology Officer at Vaxess Technologies, a Cambridge, MA, based biotechnology company researching thermostabilization of vaccines and biologics using silk fibroin protein. Prior to this, he served as Chief Scientific Officer at Hookipa Biotech in Vienna, Austria, developing vaccines against Cytomegalovirus and cancers based on a novel replication deficient viral vector platform. Prior to that, Dr. Guirakhoo held the position of Executive Director of External R&D at Sanofi Pasteur from 2007-20012. Before joining Sanofi Pasteur in 2007, Dr. Guirakhoo was Head of Virology Research at Acambis for 15 years. During this time, he co-invented the ChimeriVax™ technology platform in association with St. Louis University. This platform utilizes the YF 17D vaccine virus as a vector to develop chimeric live viruses. The ChimeriVax™ vector platform was successfully used in the development of innovative vaccines such as: a) a single dose vaccine against Japanese encephalitis (IMOJEV™), marketed in Asian countries by Sanofi, b) a single dose veterinary vaccine for the prevention of West Nile encephalitis (PREVNILE™), marketed by Merck Animal Health, and c) DENGVAXIA®, the world’s first dengue vaccine approved in Mexico and Brazil in December 2015 and marketed by Sanofi. This tetravalent vaccine represents a historic milestone for half of the world population who lives at risk of dengue. Dr. Guirakhoo has over 30 years of experience in developing vaccines against infectious diseases. Dr. Guirakhoo holds a BSc in Biology, a MSc in genetics, and a PhD in Virology from the Medical University of Vienna, Austria, and was awarded a National Research Council post-doctoral fellowship at the National Center for Disease Control and Prevention in Fort Collins, CO, from 1990-1992.
--------------------------------------------------------------------------------------------------------
Harriet Robinson:
Dr. Robinson joined the Company as Senior Vice President, Research and Development on a part-time basis in November 2007 and on a full-time basis in February 2008, and was promoted to Chief Scientific Officer in 2010. She was elected to the Board of Directors in June 2008. Dr. Robinson is the developer of GeoVax's HIV/AIDS vaccine technology and is one of the world's leaders in HIV/AIDS vaccine research. She co-founded GeoVax in 2001 to facilitate taking the AIDS vaccine developed in her laboratory at the Emory Vaccine Center in collaboration with scientists at the National Institutes of Health into the clinic. From 1999 to February 2008, Dr. Robinson served as the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University in Atlanta, Georgia, and from 1998 to February 2008 as Chief, Division of Microbiology and Immunology, Yerkes National Primate Research Center. She was a Professor in the Department of Pathology at the University of Massachusetts Medical Center from 1988 to 1997 and Staff, then Senior, then Principal Scientist at the Worcester Foundation for Experimental Biology from 1977 to 1987. Dr. Robinson received a bachelor of arts degree from Swarthmore College and M.S. and Ph.D. degrees from the Massachusetts Institute of Technology.
NVAX 308 Million Market Cap
MYMX 20 Million Market CAp
GOVX 2.5 Million Market CAp
$GOVX
Researcher: Zika vaccine could be ready in two years
http://video.foxnews.com/v/4748774457001/?#sp=show-clips
Watch the tail end of this short video GOVX is going to skyrocket....
https://www.geovax.com/clinical-pipeline.html
$GOVX
$NVAX 350 Million Market Cap
$MYMX 20 Million Market Cap
$GOVX 2.5 Million Market Cap
GOVX has a deeper pipeline than Nvax and Mymx and some of the most world renown vaccine scientist in the world.
Quantum move is coming for GOVX.
$GOVX
Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV
Proven vaccine for Ebola animal models Clinical human trials
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry
Recently updated Pipeline data on website hint hint.....
https://www.geovax.com/clinical-pipeline.html
$GOVX
Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space.
GOVX 2.5 Million Market Cap.
A 25-50 Million Market cap would still be cheap with the personal and Pipeline they have its going to happen....
$GOVX
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)
This 2.5 Million Market Cap will quadruple sooner than later.......
https://www.geovax.com/investors.html
$GOVX
http://denver.cbslocal.com/2017/08/31/health-problems-harvey/
West Nile Virus and Zika Virus are likely to be big players in the area as mosquito larvae hatch, and mosquitoes breed and bite as we get into September. In fact, after Katrina, cases of West Nile more than doubled within one month’s time.
August 30, 2017 10:00 ET
GeoVax Presents Zika Vaccine Data at Scientific Conference
Vaccine Based on Zika NS1 Protein Achieved 100% Protection in Lethal Challenge Model with a Single Immunization
ATLANTA, GA--(Marketwired - Aug 30, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, gave a comprehensive presentation of results from studies of GeoVax's NS-1 based Zika vaccine. Dr. Guirakhoo delivered the talk, entitled "A Novel Alternative Approach to Develop a Safe Vaccine for Zika," today during the Advances in Vaccine Technologies session at the Immuno-Oncology Summit in Boston, MA.
Dr. Guirakhoo presented research showing that a single dose of GeoVax's Zika vaccine gave 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV NS1 protein, and ii) single-dose full protection against ZIKV using an immunocompetent lethal mouse challenge model.
The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO. with funding by a grant from the CDC. In the study, outbred immunocompetent mice were exposed to a lethal challenge dose of ZIKV delivered directly into the brain. A single dose of GeoVax's NS1 vaccine candidate protected 100% of vaccinated animals. In contrast, 80-90% of sham-immunized control animals died within ~7 days.
GeoVax selected the ZIKV NS1 antigen as the target immunogen for its vaccine, as recent findings indicate a potential risk of disease enhancement using traditional Zika vaccine approaches based on the ZIKV envelope proteins. This "Antibody Dependent Enhancement (ADE) of infection" phenomena has been shown between ZIKV and related flaviviruses, such as West Nile and dengue, in both in vitro and in vivo studies. Mice given dengue or West Nile anti-envelope antibodies were more likely to die in the 2 weeks after the ZIKV infection than mice without these antibodies. An NS1-based vaccine avoids the ADE risk since this protein is not packaged into the virus particles, and is not involved in ADE. This approach holds the promise for a highly effective, yet safer than enveloped based Zika vaccine for humans who live in the areas where the Zika virus co-circulates with other flaviviruses.
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
http://www.marketwired.com/press-release/geovax-presents-zika-vaccine-data-at-scientific-conference-2232000.htm
$GOVX
Lots of accumulation going on Trades verified..
30K investment of mine hits a cool Million if this hits one dollar......
Seen companies that didn't have the personnel or the pipeline GOVX does and
hit multiple dollars.
https://www.geovax.com/clinical-pipeline.html
GOVX Market cap is 2.2 Million GOVX is trading .03 Cents
Not for Long you can make book on that!
GOVX 68 Million Shares.
GOVX has about a Million in Cash gets lots of funding from government agencies.
10% held by Insiders including Emory University.
This stock should be trading at least a $1.00+ They have one of the furthest HIV Vaccine in the world up to Phase 2B tested on 100's of patients and having a single shot Functional Cure Trial Starting in the next couple months.
IN ALL MY YEARS OF INVESTING I HAVE NEVER SEEN A DEEP PIPELINE LIKE THIS WITH A MARKET CAP UNDER 100 MILLION.
And Farshad Guirakhoo, Ph.D., Chief Scientific Officer for GOVX is rated #22 in the world
Thomas P. Monath, MD, (Chairman) Scientific Advisory Board # 2 Top Most Influential Vaccine Scientist in the world.
Stanley A. Plotkin Scientific Advisory Board , MD #5 Top Most Influential Vaccine Scientist in the world.
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
GOVX has three of the top 50 influential vaccine scientist in the world.
Plus Harriet Robinson One of the top HIV Researchers in the world she helped start this company with Emory University.
https://www.geovax.com/the-need-for-an-hiv-aids-vaccine.html
11 Vaccines in Clinical Trials.
Including a single shot Zika Virus, Ebola, Malaria Hep B, Marburg and Lassa fever viruses. .
And Cancer Immunotherapy Vaccines in the works.
I can see this stock moving 5,000-10,000%+ from these levels or higher..
I own over a Million Shares and see myself making a fortune here.
$GOVX
2.5 Million Market Cap some of the top vaccine scientist on board.
Deep pipeline .
Over $50 Million in Grants.
We will hear some Milestone updates soon.
So many vaccines there all Massive this company literally tests and partners with CDC and NIH & many top notch Universities..
Entering Cancer Immunotherapy. We could move 400-500% in a day on the right update.
https://www.geovax.com/clinical-pipeline.html
11 drugs in the pipeline more than some multi billion dollar biotech companies
You have the top vaccine scientist in the world at GOVX
#2 Thomas P. Monath, MD, (Chairman)
#5 Stanley A. Plotkin, MD
#22 Farshad Guirakhoo, Ph.D., Chief Scientific Officer
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
https://www.geovax.com/investors.html
5,000%-10,000 Gains here potentially .
$GOVX
Anytime......Re that!
$MGTI
Roger That.
If I would listened to the noise I would of missed out
Big on OWC- under .10 to $3.00
INM-at .0075 to over .03
MGT- from 1.80 till we will see
MNK- from .85 to over $2.25
We have had some tremendous stocks that made us a small fortune. GOVX will make it rain dolla dolla bills yall...
https://www.geovax.com/investors.html
Investors
We are committed to providing our shareholders with accessible, complete information about our company. Within this section of the website, you will find comprehensive stock information, corporate data and progress reports.
Investment Highlights
Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)
Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry
https://www.geovax.com/clinical-pipeline.html
When you run from around .50 to $4.25
Days like this will happen.
Stop losses where taken out today.
The weak ones got shaken
1.Sentinel
2. Privacy Phone
3. Largest Bitcoin Miner.
I'm up huge and will add tomorrow!
Best Bitcoin Play out there Bitcoin will continue to Surge. And so will MGTI.
$MGTI
We are going to hit gold Here Starkd.
$GOVX
LOL are you kidding me. Ruff Ruff
:)
Cant have it both ways
NVAX 308 Million MC
GOVX 2.5 Million MC
https://www.geovax.com/clinical-pipeline.html
$GOVX
LMAO LOL
Luckydog83 Saturday, 07/29/17 08:57:05 AM
Re: Apophis post# 4327
Post #
4337
of 4446 Go
As of June 14, 2017...
https://www.geovax.com/pdf/GeoVax-Executive-Informational-Overview-06-15-17_S_FINAL.pdf
Don't tell anyone! I'm still accumulating.
thx!
gltu!
From Luckydog
Nice buying frenzy today... ALL BUYS right up to .041!
Time Buy
26 nasd 0.041 1,800 0.038 0.041 14:00:07 1,800 565,991 0 1,450
25 nasd 0.04 60,000 0.038 0.04 13:59:29 60,000 564,191 0 1,450
24 nasd 0.04 10,000 0.038 0.04 13:58:05 10,000 504,191 0 1,450
23 nasd 0.039 110,000 0.038 0.039 13:57:42 110,000 494,191 0 1,450
22 nasd 0.039 14,390 0.038 0.039 13:57:12 14,390 384,191 0 1,450
21 nasd 0.039 10,000 0.038 0.039 13:57:08 10,000 369,801 0 1,450
20 nasd 0.0385 1,450 0.038 0.039 13:56:19 1,450 359,801 0 1,450
19 nasd 0.039 52,500 0.038 0.039 13:55:24 52,500 359,801 0 0
18 nasd 0.039 10,000 0.038 0.039 13:55:02 10,000 307,301 0 0
17 nasd 0.039 2,408 0.038 0.039 13:53:37 2,408 297,301 0 0
16 nasd 0.039 65,000 0.0375 0.039 13:53:30 65,000 294,893 0 0
15 nasd 0.039 10,000 0.0375 0.039 13:53:13 10,000 229,893 0 0
14 nasd 0.039 5,000 0.0375 0.039 13:30:03 5,000 219,893 0 0
13 nasd 0.0385 5,000 0.0375 0.039 13:29:56 5,000 214,893 0 0
12 nasd 0.039 55,000 0.0375 0.039 10:37:58 55,000 209,893 0 0
11 nasd 0.039 42,000 0.0375 0.039 10:33:35 42,000 154,893 0 0
10 nasd 0.039 2,500 0.0375 0.039 10:33:31 2,500 112,893 0 0
9 nasd 0.039 2,500 0.038 0.039 10:33:01 2,500 110,393 0 0
8 nasd 0.039 2,500 0.038 0.039 10:32:31 2,500 107,893 0 0
7 nasd 0.039 40,000 0.0375 0.039 09:54:25 40,000 105,393 0 0
6 nasd 0.039 30,000 0.0375 0.039 09:54:25 30,000 65,393 0 0
5 nasd 0.039 4,893 0.0375 0.039 09:50:52 4,893 35,393 0 0
4 nasd 0.039 10,000 0.0375 0.039 09:45:11 10,000 30,500 0 0
3 nasd 0.039 10,000 0.0375 0.039 09:45:10 10,000 20,500 0 0
2 nasd 0.039 500 0.0375 0.039 09:30:18 500 10,500 0 0
1 nasd 0.039 10,000 0.0375 0.039 09:30:18 10,000 10,000 0 0
IF i listened to people swaying me from getting in on undervalued companies it would of prevented me from making six figures each of the past few months I would of missed out. > I do my homework thanks. Unbelievable..........
You bought high sold low and is upset :)
This company has the leadership and the pipelines.
These are the rare unhidden gems you can get in at a few pennies and ride it to dollars.
This company has double digit dollar potential.
I missed out on PCYC when it was an OTC not going to miss another golden opportunity...
$GOVX
From the last 10Q
As of August 14, 2017, 66,913,900 shares of the Registrant’s common stock, $.001 par value, were issued and outstanding.
If you look at the volume there is very little if any dilution over the past year.....
They have little less than a Million in cash
Company gets grants from NIH and CDC they construct and partner with them & many universities.. Also they get money from non profits looking to develop vaccines..
I had an extensive conversation with the CEO he is in the office. Secretary and all this isn't your typical OTC biotech play. I will make bank here!
$GOVX
Investors
https://www.geovax.com/investors.html
This is the most undervalued company on the OTCQB hands down.
We are committed to providing our shareholders with accessible, complete information about our company. Within this section of the website, you will find comprehensive stock information, corporate data and progress reports.
Investment Highlights
Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and
distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space.
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)
Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date.
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry.
$GOVX
Wednesday, 30 August 2017
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be presenting preliminary results from studies of GeoVax’s MUC1 cancer vaccine in collaboration with ViaMune, Inc. today at the Advances in Vaccine Technologies session at the Immuno-Oncology Summit in Boston, MA.
GeoVax and ViaMune are each developing products that target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is overexpressed in metastatic cancers (e.g. breast, pancreatic, lung, and ovarian cancers) and circulating tumor cells and which is often used as a diagnostic marker for cancer progression. Due to overexpression and/or aberrant glycosylation of MUC1, this “tumor-associated antigen” (TAA) is often recognized as abnormal by a patient’s immune system but is not sufficiently immunogenic to trigger an effective immune response shown to be associated with significant increase in overall survival of patients. Therefore, this or any TAA must be presented to the body in a different form, or in a different way, to recruit the patient’s own immune system to fight the cancer. GeoVax and ViaMune are collaborating with the goal of developing a tumor MUC1 vaccine that can produce a broad spectrum of anti-tumor antibody and T cell responses.
In a human MUC1 colon adenocarcinoma mouse tumor model, groups of hMUC1 transgenic mice with established tumors were treated with MTI (ViaMune’s synthetic vaccine), MVA-VLP-MUC1 (GeoVax’s viral-vectored vaccine) or a combination of both. All treatment groups received an immune checkpoint inhibitor in the form of an anti-PD-1 antibody. The preliminary results from two studies indicate that a combined vaccine approach can increase the activity of anti-PD-1 therapy. The studies were performed by the laboratory of Dr. Pinku Mukherjee, PhD, at the University of North Carolina at Charlotte.
https://www.geovax.com/immuno-oncology-program.html
$GOVX
Dr. Guirakhoo commented, “We are pleased with the data from this study, which are encouraging and demonstrate a potentially synergistic effect between the GeoVax and ViaMune vaccines. This study gives us the scientific justification to pursue additional investigation of our approach, and we intend to seek funding to vigorously pursue development of the combined MVA-MTI technologies for the treatment of multiple cancer indications.”
$GOVX
GeoVax Labs, Inc. (OTCQB: GOVX), August 30th a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, gave a comprehensive presentation of results from studies of GeoVax’s NS-1 based Zika vaccine. Dr. Guirakhoo delivered the talk, entitled “A Novel Alternative Approach to Develop a Safe Vaccine for Zika,” today during the Advances in Vaccine Technologies session at the Immuno-Oncology Summit in Boston, MA.
Dr. Guirakhoo presented research showing that a single dose of GeoVax’s Zika vaccine gave 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV NS1 protein, and ii) single-dose full protection against ZIKV using an immunocompetent lethal mouse challenge model.
The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO. with funding by a grant from the CDC. In the study, outbred immunocompetent mice were exposed to a lethal challenge dose of ZIKV delivered directly into the brain. A single dose of GeoVax’s NS1 vaccine candidate protected 100% of vaccinated animals. In contrast, 80-90% of sham-immunized control animals died within ~7 days.
GeoVax selected the ZIKV NS1 antigen as the target immunogen for its vaccine, as recent findings indicate a potential risk of disease enhancement using traditional Zika vaccine approaches based on the ZIKV envelope proteins. This “Antibody Dependent Enhancement (ADE) of infection” phenomena has been shown between ZIKV and related flaviviruses, such as West Nile and dengue, in both in vitro and in vivo studies. Mice given dengue or West Nile anti-envelope antibodies were more likely to die in the 2 weeks after the ZIKV infection than mice without these antibodies. An NS1-based vaccine avoids the ADE risk since this protein is not packaged into the virus particles, and is not involved in ADE. This approach holds the promise for a highly effective, yet safer than enveloped based Zika vaccine for humans who live in the areas where the Zika virus co-circulates with other flaviviruses.
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) vaccine platform. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
$GOVX
http://www.thevaccinereaction.org/2016/11/global-vaccine-market-surging-to-more-than-70-billion-by-2024/
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
https://www.geovax.com/clinical-pipeline.html
GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update
Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer
ATLANTA, GA--(Marketwired - Aug 7, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its financial results for the quarter ended June 30, 2017, and provided an overview of recent accomplishments for its research and development programs.
Robert T. McNally Ph.D., GeoVax's President and CEO, commented, "To date, 2017 has been marked by several important achievements further demonstrating the excellent efficacy and broad utility of our MVA-VLP vaccine platform, as well as scientific recognition through our growing list of exceptional corporate and academic collaborators. We continue to engage in active discussions with additional research collaborators and potential strategic partners. I am pleased to provide this update on our progress."
2017 Highlights To Date:
Progress in Zika Vaccine Development. In June, at the American Society for Microbiology (ASM) conference (ASM MICROBE 2017), GeoVax presented research showing that a single dose of its Zika vaccine (GEO-ZM02) gave 100% protection in mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV non-structural (NS1) protein, and ii) single-dose protection against ZIKV using an immunocompetent lethal mouse challenge model. The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO with funding by a grant from the CDC. Importantly, GeoVax's approach to a Zika vaccine is unique as it is based on the NS1 protein of ZIKV and thus will avoid the Antibody Dependent Enhancement (ADE) of infection safety issue, which is a concern for other Zika vaccines under development.
Also in June, the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded GeoVax a Small Business Innovative Research (SBIR) grant of $600,000 to support advanced preclinical testing, including non-human primates studies, for its Zika vaccine development program in preparation for a Phase 1 human clinical study.
Promising Results for Lassa Fever Vaccine. In July, GeoVax reported a significant step forward in the development of a vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a chimeric LASV reassortant) showed a single dose of GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus. The study was conducted, and successfully repeated, at the Institute of Human Virology at the University of Maryland School of Medicine. GeoVax recently expanded its LASV vaccine development efforts through a collaboration with The Scripps Research Institute. With no vaccine available, LASV continues to kill more than 5000 people each year in West African countries where the virus is endemic.
Earlier, a single dose of GeoVax's Ebola (EBOV) vaccine (GEO-EM01) was shown to protect 100% of vaccinated monkeys against death. GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal hemorrhagic fever viruses for which no effective vaccine currently exists. In addition to developing the four individual hemorrhagic fever vaccines (EBOV, LASV, SUDV, MARV), the Company's goal is to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses.
HIV Preventive Vaccine Development - New Clinical Trial Begun with NIH Support. In January, GeoVax initiated a human clinical trial of its preventive HIV vaccine, GOVX-B11, being developed to address the clade B HIV subtype prevalent in the U.S. and other areas of the developed world. The Phase 1 trial (designated HVTN 114) is being conducted by the HIV Vaccine Trials Network (HVTN) with funding from NIAID. HVTN 114 will enroll up to 30 individuals who participated in an earlier Phase 2a trial of GOVX-B11 and will test the ability of additional vaccinations to increase the antibody responses elicited by the GeoVax vaccine.
During 2017, GeoVax continued its work under a NIAID contract of up to $7.8 million for production of the DNA component of GOVX-B11 intended for later-stage clinical trials. The Company also continued work under two SBIR grants from NIAID for both its clade B HIV vaccine, and for its vaccine for the clade C HIV subtype prevalent in Africa.
HIV Therapeutic Vaccine Development - Collaboration to Focus on Functional Cure. In March, GeoVax began a collaboration with American Gene Technologies International, Inc. (AGT) with the goal of developing a functional cure for HIV infection. The Company expects AGT to file an Investigation New Drug (IND) application later this year and to initiate human clinical trials of the companies' combined technologies in early 2018.
Malaria Vaccine Program Initiated. In January, GeoVax initiated a new program to develop a malaria vaccine using its MVA-VLP viral vector platform through collaboration with The Burnet Institute in Australia. The Company has completed construction of 4 vaccine candidates and expects the initial preclinical proof-of-concept studies to commence in September 2017.
Ongoing Therapeutic Development Programs for Chronic Hepatitis B and Cancer. During the first quarter, GeoVax added Georgia State University and Peking University as collaborators to develop a therapeutic vaccine for chronic Hepatitis B infection. Initial preclinical proof-of-concept studies are ongoing. GeoVax is also continuing its collaboration with ViaMune, Inc. for co-development of the companies' respective cancer immunotherapy programs, with initial and confirmatory data readouts expected during the third quarter.
Establishment of World-Class Scientific Advisory Board. In January, GeoVax formed a Scientific Advisory Board composed of world-class scientists including Thomas Monath, MD; Stanley Plotkin, MD; Barney Graham, MD, PhD; Scott Weaver, PhD; and Olivera Finn, PhD. This expert group is already making its mark through their direction and advice for the Company's various development programs.
Financial Review
GeoVax reported a net loss of $516,881 ($0.01 per share) for the three months ended June 30, 2017, compared to $575,835 ($0.02 per share) for the same period in 2016. For the six months ended June 30, 2017, the Company's net loss was $1,065,222 ($0.02 per share) as compared to $1,872,114 ($0.05 per share) in 2016.
The Company reported grant and collaboration revenues of $352,137 and $647,872 for the three-month and six-month periods of 2017, respectively. This compares to $166,280 and $213,880 of grant revenue reported for the comparable periods of 2016. As of June 30, 2017, there is $910,774 in approved grant funds remaining and available for use.
Research and development (R&D) expenses were $518,098 and $1,069,893 for the three-month and six- month periods of 2017, respectively, as compared to $397,576 and $835,580 for the comparable periods of 2016. R&D expenses include direct costs funded by NIH grants, as well as other vaccine manufacturing and testing costs. General and administrative (G&A) expenses were $352,191 and $644,858 for the three-month and six-month periods of 2017, respectively, as compared to $344,818 and $1,251,323 for the comparable periods of 2016.
GeoVax reported cash balances of $822,597 at June 30, 2017, as compared to $454,030 at December 31, 2016. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
GOVX clinical trials and research grants over $50 million to date) ... Guirakhoo has filed over 90 patent applications in his scientific career, ...
$GOVX
NVAX 308 Million MC
GOVX 2.5 Million MC
I'm long both tremendous upside on both vaccine companies...
http://www.thevaccinereaction.org/2016/11/global-vaccine-market-surging-to-more-than-70-billion-by-2024/
$NVAX
GOVX Pipeline
https://www.geovax.com/clinical-pipeline.html
NVAX Pipeline
http://novavax.com/page/11/clinical-stage-pipeline
Here is the distinction GOVX has three of the worlds top vaccine scientists.. NVAX doesn't
#2 Dr Thomas Monath
https://www.bloomberg.com/research/stocks/private/person.asp?personId=438538&privcapId=9206677
#5 Dr Stan Plotkin
Emeritus ProfessorUniversity of Pennsylvania ProfessorJohns Hopkins University.
https://en.wikipedia.org/wiki/Stanley_Plotkin
#22 Dr Farshad Guirakhoo Chief Scientific Officer
Dr. Guirakhoo joined GeoVax as Senior Vice President of Research and Development in October 2015 and was promoted to Chief Scientific Officer in January 2017. Dr. Guirakhoo was named one of the ‘50 Most Influential People in Vaccines’ in Vaccine Nation’s 2014 list. His previous assignment was Chief Technology Officer at Vaxess Technologies, a Cambridge, MA, based biotechnology company researching thermostabilization of vaccines and biologics using silk fibroin protein. Prior to this, he served as Chief Scientific Officer at Hookipa Biotech in Vienna, Austria, developing vaccines against Cytomegalovirus and cancers based on a novel replication deficient viral vector platform. Prior to that, Dr. Guirakhoo held the position of Executive Director of External R&D at Sanofi Pasteur from 2007-20012. Before joining Sanofi Pasteur in 2007, Dr. Guirakhoo was Head of Virology Research at Acambis for 15 years. During this time, he co-invented the ChimeriVax™ technology platform in association with St. Louis University. This platform utilizes the YF 17D vaccine virus as a vector to develop chimeric live viruses. The ChimeriVax™ vector platform was successfully used in the development of innovative vaccines such as: a) a single dose vaccine against Japanese encephalitis (IMOJEV™), marketed in Asian countries by Sanofi, b) a single dose veterinary vaccine for the prevention of West Nile encephalitis (PREVNILE™), marketed by Merck Animal Health, and c) DENGVAXIA®, the world’s first dengue vaccine approved in Mexico and Brazil in December 2015 and marketed by Sanofi. This tetravalent vaccine represents a historic milestone for half of the world population who lives at risk of dengue. Dr. Guirakhoo has over 30 years of experience in developing vaccines against infectious diseases. Dr. Guirakhoo holds a BSc in Biology, a MSc in genetics, and a PhD in Virology from the Medical University of Vienna, Austria, and was awarded a National Research Council post-doctoral fellowship at the National Center for Disease Control and Prevention in Fort Collins, CO, from 1990-1992.
--------------------------------------------------------------------------------------------------------
Harriet Robinson:
Dr. Robinson joined the Company as Senior Vice President, Research and Development on a part-time basis in November 2007 and on a full-time basis in February 2008, and was promoted to Chief Scientific Officer in 2010. She was elected to the Board of Directors in June 2008. Dr. Robinson is the developer of GeoVax's HIV/AIDS vaccine technology and is one of the world's leaders in HIV/AIDS vaccine research. She co-founded GeoVax in 2001 to facilitate taking the AIDS vaccine developed in her laboratory at the Emory Vaccine Center in collaboration with scientists at the National Institutes of Health into the clinic. From 1999 to February 2008, Dr. Robinson served as the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University in Atlanta, Georgia, and from 1998 to February 2008 as Chief, Division of Microbiology and Immunology, Yerkes National Primate Research Center. She was a Professor in the Department of Pathology at the University of Massachusetts Medical Center from 1988 to 1997 and Staff, then Senior, then Principal Scientist at the Worcester Foundation for Experimental Biology from 1977 to 1987. Dr. Robinson received a bachelor of arts degree from Swarthmore College and M.S. and Ph.D. degrees from the Massachusetts Institute of Technology.
NVAX 308 Million MC
GOVX 2.5 Million MC
$GOVX
Solid day!
Much more upside from here.
$MNKD
NVAX Market cap 308 Million MC
GOVX 2.5 Million MC
GOVX has a more extensive pipeline and a leadership that dwarfs its competition..
$GOVX
Shorty is going to get his clocked cleaned.
GOVX is about to make a surge to a .25+ for starters..........
You can make book on that!
$GOVX
This company has more upside than any other OTCQB stock I have seen in years..
$GOVX
There a multi Billion Dollar Biotech companies with a lot less in the pipeline and no where near the world renown team GOVX has in place..
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
GOVX has three of the top Vaccine Scientist on the world on Board. Monster gains are coming with or with out you!
#2
#5
#22 this is our chief medical scientist he has developed multiple vaccines to market.
https://www.geovax.com/clinical-pipeline.html
Harriet Robinson the leading pioneer researcher in HIV helped create this company and is working on developing the many HIV vaccines GOVX has in the pipeline...
https://www.geovax.com/
$GOVX
Obviously people are confused 11 CLINICAL TRIALS here is the update all here in black and white. people feeding you mis information you will miss a multi thousand percent run coming.
Corporate update on all 11 Clinical trials.... from a few weeks ago!
GOVX 2.5 Million Market Cap 68 Million shares these are the facts..............
http://m.marketwired.com/press-release/geovax-reports-2017-second-quarter-financial-results-and-provides-corporate-update-otcqb-govx-2229160.htm
Pipeline:
https://www.geovax.com/clinical-pipeline.html
Updated Pipeline last few weeks!
August 07, 2017 09:00 ET
GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update
Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer
ATLANTA, GA--(Marketwired - Aug 7, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its financial results for the quarter ended June 30, 2017, and provided an overview of recent accomplishments for its research and development programs.
Robert T. McNally Ph.D., GeoVax's President and CEO, commented, "To date, 2017 has been marked by several important achievements further demonstrating the excellent efficacy and broad utility of our MVA-VLP vaccine platform, as well as scientific recognition through our growing list of exceptional corporate and academic collaborators. We continue to engage in active discussions with additional research collaborators and potential strategic partners. I am pleased to provide this update on our progress."
2017 Highlights To Date:
Progress in Zika Vaccine Development. In June, at the American Society for Microbiology (ASM) conference (ASM MICROBE 2017), GeoVax presented research showing that a single dose of its Zika vaccine (GEO-ZM02) gave 100% protection in mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV non-structural (NS1) protein, and ii) single-dose protection against ZIKV using an immunocompetent lethal mouse challenge model. The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO with funding by a grant from the CDC. Importantly, GeoVax's approach to a Zika vaccine is unique as it is based on the NS1 protein of ZIKV and thus will avoid the Antibody Dependent Enhancement (ADE) of infection safety issue, which is a concern for other Zika vaccines under development.
Also in June, the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded GeoVax a Small Business Innovative Research (SBIR) grant of $600,000 to support advanced preclinical testing, including non-human primates studies, for its Zika vaccine development program in preparation for a Phase 1 human clinical study.
Promising Results for Lassa Fever Vaccine. In July, GeoVax reported a significant step forward in the development of a vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a chimeric LASV reassortant) showed a single dose of GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus. The study was conducted, and successfully repeated, at the Institute of Human Virology at the University of Maryland School of Medicine. GeoVax recently expanded its LASV vaccine development efforts through a collaboration with The Scripps Research Institute. With no vaccine available, LASV continues to kill more than 5000 people each year in West African countries where the virus is endemic.
Earlier, a single dose of GeoVax's Ebola (EBOV) vaccine (GEO-EM01) was shown to protect 100% of rhesus monkeys against death. GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal hemorrhagic fever viruses for which no effective vaccine currently exists. In addition to developing the four individual hemorrhagic fever vaccines (EBOV, LASV, SUDV, MARV), the Company's goal is to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses.
HIV Preventive Vaccine Development - New Clinical Trial Begun with NIH Support. In January, GeoVax initiated a human clinical trial of its preventive HIV vaccine, GOVX-B11, being developed to address the clade B HIV subtype prevalent in the U.S. and other areas of the developed world. The Phase 1 trial (designated HVTN 114) is being conducted by the HIV Vaccine Trials Network (HVTN) with funding from NIAID. HVTN 114 will enroll up to 30 individuals who participated in an earlier Phase 2a trial of GOVX-B11 and will test the ability of additional vaccinations to increase the antibody responses elicited by the GeoVax vaccine.
During 2017, GeoVax continued its work under a NIAID contract of up to $7.8 million for production of the DNA component of GOVX-B11 intended for later-stage clinical trials. The Company also continued work under two SBIR grants from NIAID for both its clade B HIV vaccine, and for its vaccine for the clade C HIV subtype prevalent in Africa.
HIV Therapeutic Vaccine Development - Collaboration to Focus on Functional Cure. In March, GeoVax began a collaboration with American Gene Technologies International, Inc. (AGT) with the goal of developing a functional cure for HIV infection. The Company expects AGT to file an Investigation New Drug (IND) application later this year and to initiate human clinical trials of the companies' combined technologies in early 2018.
Malaria Vaccine Program Initiated. In January, GeoVax initiated a new program to develop a malaria vaccine using its MVA-VLP viral vector platform through collaboration with The Burnet Institute in Australia. The Company has completed construction of 4 vaccine candidates and expects the initial preclinical proof-of-concept studies to commence in September 2017.
Ongoing Therapeutic Development Programs for Chronic Hepatitis B and Cancer. During the first quarter, GeoVax added Georgia State University and Peking University as collaborators to develop a therapeutic vaccine for chronic Hepatitis B infection. Initial preclinical proof-of-concept studies are ongoing. GeoVax is also continuing its collaboration with ViaMune, Inc. for co-development of the companies' respective cancer immunotherapy programs, with initial and confirmatory data readouts expected during the third quarter.
Establishment of World-Class Scientific Advisory Board. In January, GeoVax formed a Scientific Advisory Board composed of world-class scientists including Thomas Monath, MD; Stanley Plotkin, MD; Barney Graham, MD, PhD; Scott Weaver, PhD; and Olivera Finn, PhD. This expert group is already making its mark through their direction and advice for the Company's various development programs.
Financial Review
GeoVax reported a net loss of $516,881 ($0.01 per share) for the three months ended June 30, 2017, compared to $575,835 ($0.02 per share) for the same period in 2016. For the six months ended June 30, 2017, the Company's net loss was $1,065,222 ($0.02 per share) as compared to $1,872,114 ($0.05 per share) in 2016.
The Company reported grant and collaboration revenues of $352,137 and $647,872 for the three-month and six-month periods of 2017, respectively. This compares to $166,280 and $213,880 of grant revenue reported for the comparable periods of 2016. As of June 30, 2017, there is $910,774 in approved grant funds remaining and available for use.
Research and development (R&D) expenses were $518,098 and $1,069,893 for the three-month and six- month periods of 2017, respectively, as compared to $397,576 and $835,580 for the comparable periods of 2016. R&D expenses include direct costs funded by NIH grants, as well as other vaccine manufacturing and testing costs. General and administrative (G&A) expenses were $352,191 and $644,858 for the three-month and six-month periods of 2017, respectively, as compared to $344,818 and $1,251,323 for the comparable periods of 2016.
GeoVax reported cash balances of $822,597 at June 30, 2017, as compared to $454,030 at December 31, 2016. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
$GOVX
My spider senses say imminent break out.
GOVX can run on air 2 Million Market Cap 68 million shares one of the furthest HIV vaccines tested on 100s of patients phase 2B coming.
11 clinical trials on blockbuster game changing vaccines!
Riding a stock from a few pennies to a few dollars is epic! Been there done that!
Timing is everything!
$GOVX
10k from a few weeks ago 68 million shares this is severely under valued pipeline is incrediable!
The pipeline was just updated on the website!
Monster move coming.
Fast tracking on single shot cure for Zika and HIV coming plus almost a dozen different diseases look at all the recent news updates on the wide array of clinical trials in motion!
Hepatitis, Ebola, malaria the vaccine market in 5 years will be 70 billion
GOVX does testing with CDC and many government agaencies and non profits.
They have received over 50 million in grants! These are facts
3 of the top vaccine scientist in the world. World renown leadership team. There are lots of things cooking here. They are busy doing presentations at big health conferences all over the world!
$GOVX
What are u talking about your pushing a stock and then tearing it down 20 min later! I can't wait till this launches charts says massive move coming! nice try getting cheap shares u are now on Ignore!
$GOVX
It's so funny how people try and post mis information while there accumulating shares!
$GOVX
Just bounced of the 52 week low. Nice volume and accumulation I just read the 10k 68 million shares there is no dumping obviously by looking at the share volume. You have no idea what your talking about!
$GOVX
This is going to launch soon.
Chart formation is ready for an parabolic break out!
3 top vaccine scientist on the planet at GOVX
$GOVX
Updated pipeline just talked to the CEO yesterday read all the new press releases on the wide array of Pipeline
It's amazing 11 trials and counting it's all there!
Most undervalued play on the OTCQB!
$GOVX
https://www.geovax.com/clinical-pipeline.html
11 drugs in the pipeline more than some multi billion dollar biotech companies
You have the top vaccine scientist in the world at GOVX
#2 Thomas P. Monath, MD, (Chairman)
#5 Stanley A. Plotkin, MD
#22 Farshad Guirakhoo, Ph.D., Chief Scientific Officer
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
5,000%-10,000 Gains here.
$GOVX
Single shot cure for Zika, HIV and much more and cancer immunotherapy.
The pipeline is staggering. As it moves along it becomes more valuable.
This is the most undervalued biotech on the Planet!
$GOVX
Weeeee
$MGTi
Millions to Billions.....
$MGTI
Bitcoin is just getting started MGTI will follow Bitcoin Plus there is a Multi Billion Dollar Cyber Security angle to this company....
$MGTI